Peptides

Apitegromab

Now FDA-approved as Isembyld for SMA alongside an SMN2-targeted treatment, with separate preliminary research on lean-mass preservation during weight loss.

Positive SMA phase 3 trial and restricted FDA indication; weight-loss evidence remains phase 2

Also known as: Isembyld · apitegromab-mstn · SRK-015

Practical use

Evidence interpretation and clinical context

Use the current name and indication: Identify Isembyld and the existing SMN2-treatment requirement when discussing approval.
Keep the endpoints separate: Report motor-scale change in SMA separately from body-composition change during weight loss.
Include the fracture warning: A muscle-directed mechanism does not remove the need to consider bone health and adverse outcomes.

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

Current US indication — primary or official source

Overview

Apitegromab is a monoclonal antibody targeting inactive forms of myostatin to inhibit its activation. The September 2026 US label covers adults and children aged at least two with spinal muscular atrophy who are already receiving an SMN2-targeted treatment. It does not replace that background treatment.

Risks and limitations

The current label warns about fractures, including serious events, and describes common infections, vomiting, headache and hypersensitivity. Animal findings raise fetal and reproductive concerns. The approved population and clinical monitoring context matter.

How to read this

An approval for motor function in a rare neuromuscular disease should be kept separate from a trial measuring lean mass during obesity treatment.

Research explained

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

Who was studied

SAPPHIRE enrolled 188 nonambulatory people aged 2–21 with type 2 or 3 SMA already receiving nusinersen or risdiplam.

What was found

In the primary 2–12-year analysis, the combined active groups improved HFMSE motor score by 1.8 points relative to placebo at 12 months. The separately tested higher-exposure group did not significantly differ from placebo.

What it cannot establish

The pooled positive result does not imply every exposure comparison succeeded or that healthy-user muscle building was tested.

Read the original study

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

Who was studied

102 adults with overweight or obesity randomized to apitegromab or placebo while receiving tirzepatide; 24-week analysis.

What was found

Apitegromab was associated with 1.9 kg less lean-mass loss than placebo, despite similar total weight loss.

What it cannot establish

Preserving measured lean mass is not the same as gaining muscle, and the study does not establish long-term functional benefit or an obesity approval.

Read the original study

Current US indication

Isembyld’s 2026 label specifies SMA in patients aged two or older currently receiving an SMN2-targeted treatment. Obesity and physique enhancement are outside that labeled indication.

Supporting source